A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7,5mg.kg or 15mg/kg) in addition to carboplain-based chemotherapy (gemcitabine or paclitaxed)
Grant Data
Project Title
A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7,5mg.kg or 15mg/kg) in addition to carboplain-based chemotherapy (gemcitabine or paclitaxed)
Principal Investigator
Dr Ho, James Chung Man
(Principal Investigator (PI))
Co-Investigator(s)
Dr Lam David Chi Leung
(Co-Investigator)
Dr Wong Matthew King Yan
(Co-Investigator)
Dr Lam Jamie Chung Mei
(Co-Investigator)
Dr Wang Julie Kwan Ling
(Co-Investigator)
Duration
37
Start Date
2008-12-01
Amount
271260
Conference Title
A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7,5mg.kg or 15mg/kg) in addition to carboplain-based chemotherapy (gemcitabine or paclitaxed)
Presentation Title
Keywords
biomarkers
Discipline
Respiration,Cancer
HKU Project Code
N/A
Grant Type
Pharmaceutical Industry - General Award
Funding Year
2008
Status
On-going